Phoqus Pharmaceuticals announces it has appointed Michel Grandjean to the position of Chief Operating Officer

Phoqus Pharmaceuticals announces it has appointed Dr Patrick Round to the position of Chief Medical Officer

Phoqus Pharmaceuticals today announces an update on the progress and design of the clinical trial programme for Chronocort™

Phoqus Pharmaceuticals today announces its interim results for the six months ended 30 June 2007.

Phoqus Pharmaceuticals announces that the Company's name was changed from Phoqus Group plc to Phoqus Pharmaceuticals plc.

Phoqus announces the results of the Extraordinary General Meeting.

Phoqus receives IND from FDA and initiates Phase II clinical trial of Chronocort™ in patients with Congenital Adrenal Hyperplasia at the US National Institutes of Health.

Phoqus announces the Board’s proposal to change the Company’s name to Phoqus Pharmaceuticals plc.

Phoqus announces that it has appointed Patheon as Contract Manufacturer for Clinical Supplies of Chronocort™ for Phase III Trials.

Phoqus announces the availability of the information required by AIM Rule 26 (company information disclosure).

Phoqus announces the successful completion of study #003, the third phase I clinical study of Chronocort™.

Phoqus announces that it has filed an Investigational New Drug ("IND") application with the US FDA for its lead product Chronocort™.

Phoqus announces the results of the Extraordinary General Meeting.

Phoqus announces a proposed fundraising to raise £5.0 million ($10.1 million) net of expenses by way of a Placing of new Ordinary Shares.

Phoqus receives positive regulatory opinion on Chronocort™ pivotal development plan for Congenital Adrenal Hyperplasia (CAH).

Phoqus enters collaboration with US National Institutes of Health (NIH) for clinical development of Chronocort™ for endocrine disorders.

Phoqus announces the results of the Annual General Meeting.

Phoqus announces it has appointed Dr Hiep Huatan to the key management position of Vice President, Research & Development.

Phoqus announces that that the clinical development programme for Chronocort™, its lead in-house development project for certain cortisol deficient endocrine disorders, continues to progress to plan.

Phoqus announces that the European Commission has granted Orphan Medicinal Product Designation to Chronocort™ for the treatment of adrenal insufficiency ("AI").

Phoqus has today published its report and accounts for the year ended 31 December 2006 and sent to shareholders notice of its Annual General Meeting.

Phoqus announces the appointment today of Dr. Richard Mason as the new Chief Executive Officer of the Company.

Phoqus today announces its preliminary results for the year ended 31 December 2006.